Periodic Reporting for period 1 - SPELITEC (Sequence sPecific ELImination of shiga-Toxin E. Coli)
Reporting period: 2019-04-01 to 2020-03-31
STEC primarily infect young children and are responsible for severe bloody diarrhea with serious complications (kidney failure, death). STEC outbreaks can have devastating consequences as seen with the German outbreak of 2011 that killed more than 50 people. Despite the severity of the disease, STEC infections remain an unmet medical need: antibiotics are contraindicated as they may favor the production of toxin by STEC bacteria and worsen the situation, and no other treatment strategy has been approved to treat this condition so far.
In this context the SPELITEC project aims at developing EB003, a new class of highly specific antimicrobial able to target and eliminate STEC bacteria while preventing the production of shiga toxins. Such product will bring the following advantages to patients and society:
- It will eliminate STEC pathogens from the intestines of infected patients early in the course of the disease.
- It will display an excellent safety profile and its unparalleled specificity will leave all non STEC bacteria (including beneficial microbes from the microbiota) unharmed
- It will cure patients' bloody diarrhea and prevent the serious complications of the disease (kidney failure and death).
- It will reduce the risk of STEC outbreaks as the efficient elimination of the STEC pathogen in patients’ intestines will prevent its spread to the community.
To achieve this goal, the main objectives of the SPELITEC project are:
- To transition from a laboratory-scale to an industrial-scale production of the EB003 compound to meet clinical needs
- To confirm the efficacy of EB003 in various preclinical models in vitro and in vivo.
- To confirm the safety of EB003 in regulatory toxicology models
- To obtain validation from regulatory agencies to perform first clinical trials in humans.
The manufacturing process of EB003 active substance was entirely transferred from a laboratory scale to an industrial scale compatible with clinical requirements (GMP).
→ It is the first time such a manufacturing process is put in place for that type of product. This is a great milestone for the project and significantly increases EB003’s chances of success in the clinic.
EB003 active substance was tested on a large collection of >100 STEC bacteria recently isolated from infected patients.
→ Eligo could demonstrate that the active substance of EB003 was active on >95% of the collection and could confirm its ability to eliminate STEC bacteria very efficiently (more than 99,99% of the STEC bacteria are eliminated upon treatment). These critical results suggest that EB003 will be active on the vast majority of STEC bacteria infecting patients.
EB003 active substance was tested on animal models of STEC infections.
→ Eligo could demonstrate the ability of the EB003 active substance to eliminate >99,9% of STEC bacteria from the intestine of mice only 6h after oral administration of the treatment. This is a great milestone showing that EB003 has the best chances to target and eliminate STEC in the intestines of patients.
Overall, we during this first reporting period, we demonstrated that EB003 efficiently eliminates recent STEC strains in vitro and in vivo and we secured our ability to produce EB003 at an industrial scale to meet clinical needs.
- Further demonstrating the efficacy of EB003 in other preclinical models that recapitulate more faithfully the situation of STEC infected patients
- Confirming the expected excellent safety profile of EB003 on human cells in vitro and in in vivo regulatory toxicological models.
- Obtaining the authorization from regulatory agencies to perform clinical studies in humans.